Last deal

$10M

Amount

Series A

Stage

06.10.2017

Date

2

all rounds

$10.48M

Total amount

date founded

Financing round

General

About Company
Intezyne Technologies develops synthetic polymers for drug delivery and the treatment of cancer.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2004

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

The biomedical research company has developed the IVECT Method, which delivers various classes of small molecules, nucleic acids, oligopeptides, and diagnostic imaging agents to limit chemotherapeutics' anti-tumor activity to within the tumor itself. Intezyne's pipeline of oncology products is based on synthetic polymers with multi-modal oncology compounds that combine tissue, cellular and molecular targeting with tumor-specific release mechanisms, enabling physicians to treat cancer effectively. The clinical-stage biotechnology company is focused on increasing the effectiveness of cancer treatments through the application of a diverse portfolio of proprietary assets, which are currently advancing through various stages of the clinical approval process.
Contacts

Contact Email

Phone number

Social url

Similar Companies
999
iOnctura

iOnctura

iOnctura is a clinical-stage biotech developing next-generation bio-molecules for the treatment of cancer and fibrosis.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Geneva, Switzerland

total rounds

9

total raised

$127.72M
Proacta

Proacta

Proacta Inc. is a clinical-stage biopharmaceutical company developing hypoxia-activated prodrugs for the treatment of cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

La Jolla, San Diego, CA, USA

total rounds

5

total raised

$47M
Celsion

Celsion

Celsion is a biopharmaceutical company developing innovative cancer treatments.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Lawrenceville, Lawrence Township, NJ 08648, USA

total rounds

8

total raised

$123.79M
Speratum

Speratum

Speratum is a biotechnology company that develops targeted molecular therapies for cancer treatment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San José Province, San José, Costa Rica

total rounds

3

total raised

$2.8M

Financials

Funding Rounds
2
2

Number of Funding Rounds

$10.48M

Money Raised

Their latest funding was raised on 06.10.2017. Their latest investor Gaston Capital Partners. Their latest round Series A

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Gaston Capital Partners

Gaston Capital Partners

Gaston Capital Partners is a private equity firm in Gastonia, North Carolina.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Biotechnology

Location

Belmont, CA, USA

count Of Investments

2
Co-Investors
Investors
1
1

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
Gaston Capital Partners

Gaston Capital Partners

Gaston Capital Partners is a private equity firm in Gastonia, North Carolina.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Biotechnology

Location

Belmont, CA, USA

count Of Investments

2
Michael K McMahan

Michael K McMahan

Michael K. (Mick) McMahan is the founder and Managing Partner of Gaston Capital Partners, LLC, a private equity firm in Gastonia, North Carolina. He has more than thirty-five years experience managing investment portfolios and working with small businesses. He has been listed as a top-ranked Charlotte-area financial advisor by the Charlotte Business Journal and in Barron's as one of the top 100 independent financial advisers in the country. He has successfully managed hundreds of millions of dollars in client assets since 1984. He is a popular public speaker who is sought after by numerous organizations to address audiences on topics such as financial investment advice, business management, and military service. Mick holds a Bachelor of Arts with Honors in Economics and a Masters in Public Administration from the University of North Carolina at Chapel Hill. He also completed the Certified Financial Planner program through the College for Financial Planning in Denver, CO; Investment Management and Asset Allocation through the Wharton Business School at the University of Pennsylvania; and Advanced Estate Planning through the Heckerling Institute at the University of Miami Law School.

current job

Gaston Capital Partners
Gaston Capital Partners

People

Founders
2
Kevin Sill
Kevin Sill

Kevin Sill

Kevin Sill, Ph.D., is the Chief Executive Office, Chief Science Officer, President and co-founder of Intezyne. Dr. Sill completed his Ph.D. and M.S. in polymer science and engineering at the University of Massachusetts and holds a B.S. degree in chemistry from the University of Illinois. In November of 2009, Dr. Sill received the inaugural "Young Innovator of the Year" award from R&D Magazine. He is a co-inventor on 27 issued US patents as well as 61 additional international patents and has authored or co-authored 18 peer-reviewed publications in fields spanning polymer chemistry, polymer physics, nanoparticles, and drug delivery applications. Dr. Sill is a registered US Patent Agent. As a principal investigator, he has received over $2.5M in federal research funding. Dr. Sill, a recognized expert in the field of drug delivery, serves on a NIH review panel for Biomaterials, Delivery, and Nanotechnology.

current job

BW Therapeutics
BW Therapeutics

organization founded

3

Kevin Sill

Habib Skaff
Habib Skaff

Habib Skaff

organization founded

1

Habib Skaff

Employee Profiles
7
E. Russell McAllister

E. Russell McAllister

CFO

Activity

Recent News
0